To read this content please select one of the options below:

Valproate in acute mania: is our practice evidence based?

Kamini Vasudev (London Health Sciences Centre, University of Western Ontario, London, Canada)
Anna Mead (LD Psychology Services South Tyneside, Jarrow, UK)
Karine Macritchie (Institute of Mental Health, Department of Psychiatry, University of British Columbia, Vancouver, Canada)
Allan H. Young (Institute of Mental Health, Department of Psychiatry, University of British Columbia, Vancouver, Canada)

International Journal of Health Care Quality Assurance

ISSN: 0952-6862

Article publication date: 6 January 2012

554

Abstract

Purpose

This audit was conducted on acute psychiatric in‐patient wards with the aim of establishing if valproate prescribing in acute mania followed evidence‐based guidelines with particular emphasis on formulations used and whether accelerated valproate dosing was employed.

Design/methodology/approach

Case notes from 43 (42 percent male) patients admitted with mania and subsequently discharged on valproate were reviewed. Valproate formulation, weight measurement (necessary for dose‐calculation in accelerated dosing), initial valproate dose and increments, serum valproate monitoring and other prescribed psychotropic agents were noted.

Findings

Most (95 percent) patients received sodium valproate (epilim chrono/generic), the remaining received valproate semi‐sodium (depakote). All but one patient received antipsychotic medication in combination. Weight was recorded in only four (9 percent) patients. The mean valproate daily dose after the first week was 1,027 mg (sd=408). It took 29 (sd=42) days to reach the maximum daily dose (1,426 mg sd=467) from valproate initiation. Serum levels were monitored in 34 (79 percent) cases, but the mean period between valproate initiation to the first serum level test was 38 (sd=47) days. A significant positive correlation was found between days taken to reach maximum dose and hospital stay (Spearman's rho=0.41, n=43, p=0.006, two‐tailed).

Practical implications

Accelerated valproate dosing was not common practice, which may have resulted in suboptimal efficacy, probably leading to combination treatment.

Originality/value

This study highlights the need for adequate initial dosing and dose increments when treating manic patients and suggests current practice is not evidence‐based. Local prescribing policy and national guidelines' influence on practice are discussed.

Keywords

Citation

Vasudev, K., Mead, A., Macritchie, K. and Young, A.H. (2012), "Valproate in acute mania: is our practice evidence based?", International Journal of Health Care Quality Assurance, Vol. 25 No. 1, pp. 41-52. https://doi.org/10.1108/09526861211192395

Publisher

:

Emerald Group Publishing Limited

Copyright © 2012, Emerald Group Publishing Limited

Related articles